# NYBC Ventures

NYBC Ventures is a Venture Capital based in Boston, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Boston, United States
- **Region:** North America
- **Address:** Boston, MA, United States
- **Founded:** 2022
- **Assets under management:** Undisclosed
- **Website:** www.nybcventures.org
- **LinkedIn:** https://www.linkedin.com/company/nybc-ventures

## Regulatory record

- **Reports private funds:** No

## About

NYBC Ventures is an early-stage life sciences investment fund founded in 2021 in Boston, Massachusetts. The fund focuses on accelerating innovations in blood and cellular therapies and related technologies. NYBC Ventures has made 14 investments, including a Series B investment in Vitestro on March 10, 2026.

## Sectors

- Healthcare Services
- Digital Health

## People

- Christopher D. Hillyer, MD — Investment Team
- Jay Mohr — Investment Team
- Meg Wood, MPH — Investment Team
- Kuan Yu — Investment Team

## Questions

### Who runs investment decisions at NYBC Ventures?

The investment team listed on the firm's website includes Christopher D. Hillyer, Jay Mohr, Meg Wood, and Kuan Yu. Specific titles and individual authorities are not publicly detailed. A separate board of managers—John Rosenthal, Jung Choi, Cristina Csimma, and David Kabakoff—provides governance oversight for the entity.

### How is NYBC Ventures related to New York Blood Center?

NYBC Ventures was launched by New York Blood Center Enterprises with a $50M sponsor commitment. The parent organization is a 60-year-old non-profit that runs blood collection, the Lindsley F. Kimball Research Institute, and Comprehensive Cell Solutions, a cell-and-gene therapy CDMO. The venture arm was created to commercialize innovations emerging from that research and clinical ecosystem.

### What investment stages does NYBC Ventures target?

The firm targets early to mid-stage innovations according to its published strategy. It invests in therapeutics, devices, and other breakthrough technologies within hematology, transfusion medicine, cell therapy, and infectious disease. It has not disclosed whether allocations are structured as equity, convertibles, or alternative deal structures.

### Does NYBC Ventures participate in fund commitments or only direct deals?

The firm's published materials describe a direct investment strategy targeting therapeutics, devices, and enabling technologies. There is no mention of fund-of-funds commitments, co-investment vehicles, or special-purpose vehicles in any publicly available source.

## Related profiles

- [NXT Ventures](https://altss.com/profile/nxt-ventures)
- [NYCA Partners](https://altss.com/profile/nyca-partners)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/nybc-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology